Sermorelin is a synthetic peptide corresponding to the first 29 residues of growth-hormone-releasing hormone (GHRH), the shortest fragment that retains full receptor-activating character. This minimal-active-fragment design makes it a compact, well-defined tool for studying the GHRH receptor.
Sequence rationale
Truncating native GHRH to its N-terminal 29 residues, GHRH(1-29), keeps the region responsible for engaging the GHRH receptor while trimming the remainder that is not required for activity — the basis of its mechanism of action. For a primer on how residue order defines a peptide, see understanding amino acid sequences.
The minimal active fragment
Establishing that biological activity concentrated in the first 29 residues was a key finding, described in the discovery and history of the molecule. Working with a shorter fragment simplifies synthesis and reduces cost while preserving receptor engagement, which is why sermorelin became a practical research standard.
Solid-phase assembly
Like most research peptides of this length, sermorelin is built by solid-phase peptide synthesis, assembling the 29-residue chain stepwise on a resin support. It is then cleaved from the resin, purified, and lyophilized — the drying step is explained in what is lyophilization.
Purification challenges
A 29-residue chain is long enough that truncated and deletion sequences can accumulate during synthesis, so careful chromatographic purification is essential to isolate the correct full-length product.
Confirming the product
Identity and purity of the finished peptide are documented by chromatography and mass analysis, as covered in understanding HPLC purity. Background on the molecule is in the sermorelin research overview.
Sequence-dependent stability
Sermorelin retains the native N-terminal region needed for receptor activation, but that natural-like sequence also remains susceptible to enzymatic cleavage. This is an experimental consideration rather than a synthesis defect. Assays comparing sermorelin with modified GHRH analogs should account for differences in degradation and not assume equal intact-peptide exposure from equal starting concentrations.
Material characterization
For a 29-residue peptide, a single mass value confirms overall composition but may not resolve every positional or sequence-related impurity. Chromatographic purity, mass analysis, peptide content, counterion information, and residual moisture together provide a fuller material profile. Recording these attributes supports concentration calculations and makes comparisons across batches or analogs more reproducible.
Analytical comparability
Reference standards and system-suitability checks help determine whether a method resolves the intact chain from nearby impurities. Lot comparisons should use the same chromatographic conditions because purity percentages generated by different gradients, wavelengths, or integration rules are not automatically equivalent.
Product page: Sermorelin research vials.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.